The structure and distribution of satellite cells of cardiac muscles in decapod crustaceans

Summary The structure and distribution of satellite cells of cardiac muscles were examined in twenty-one species of animals chosen from each tribe within the order Decapoda (Arthropoda, Crustacea). The satellite cells were found in all animals observed. Most of them are morphologically identical with those described in different striated muscles of other species, but some cells have unusual features. The decapod satellite cell occasionally lies right over the region corresponding to the intercalated disc between the apposed cardiac muscle cells. The cell sends cytoplasmic processes into the adjacent muscle cells, enabling the plasma membrane to make close contact with the cleft opening of the intercalated disc, and with the myofibril at the level of the Z-line. Another characteristic feature is the presence of paired cells. Such cells are clearly separated from each other over most of the contact area by the respective plasma membranes, which are smooth in appearance and devoid of specialized regions. The significance of the presence of satellite cells in decapod cardiac muscle and its possible role are discussed and compared with those described for other species.     

Differential sensitivity of cardiac K(ATP) + channels to guanine nucleotides — evidence for a heterogeneous channel population

In cell-free patches from cultured neonatal rat cardiocytes, the cytosolic presence of GTP--S (100 µmol/l) or GDP-\-S (100 µmol/1) activated K_(ATP) ⁺ channels. GTP--S required cytosolic Mg⁺⁺, suggesting that an activated G-protein causes the increase in open probability. The great variations of the channel response to GTP--S and GDP-\-S indicates that cardiac K_(ATP) ⁺ channels represent a heterogeneous family. Correspondence to: M. Kohlhardt     

Isolated cardiac myocytes A new cellular model for studying insulin modulation of monosaccharide transport

The usefulness of isolated Ca²⁺-tolerant myocytes as a cellular model system for investigating modulation of monosaccharide transport by insulin was investigated. We have found that the isolation technique described by Haworth et al. (Haworth, R.A., Hunter, D.R. and Berkoff, H.A. (1980) J. Mol. Cell. Cardiol. 12, 715–724), with some minor modifications, consistently gave the highest yield of quiescent, rod-shaped myocytes which maintained their integrity in the presence of 2 mM calcium. Using 3-O-methylglucose, a non-metabolized sugar, transport was shown to possess saturability, substrate stereospecificity, competition and countertransport; all of which have been thoroughly established for d-glucose transport in other systems. The apparent K_m of transport ranged from 2.3 to 3.5 mM. Insulin (10 nM) caused a small but significant increase in K_m and a 2–3-fold increase in V_max. These results suggest that this myocyte preparation will provide a useful model for studying the transport-related effects of insulin as well as current hypotheses regarding the mechanism of insulin modulation of transport at the cellular level.     

T-tubes in cultured mammalian myocardial cells

Summary T-tubes are among the last structural elements of the mammalian myocyte to develop in vivo. We were able to identify T-tubes in early cultures of neonatal rat myocytes. Ventricles were excised from 3- to 4-day-old neonatal rats, incubated overnight in cold trypsin, and treated with sequential changes of collagenase-hyaluronidase. Fractions of cells isolated in this manner were pooled and cultured in plastic petri dishes. In cells prepared for transmission electron microscopy, T-tubes were observed at the cell periphery of cultured myocytes, but were more difficult to identify as the cultures aged and became overgrown by fibroblasts. T-tubes were identified by virtue of their continuity with the sarcolemma, their relatively large diameter, and their regular entry at the level of the Z line. Even at optimal culture ages, T-tubes were not present in every myocyte. At the times T-tubes could be located, myocytes were beating and had begun to establish intercalated discs and gap junctions. The de novo formation of T-tubes in cultured myocytes of neonatal rat heart reflects a duplication of in vivo differentiation by the cultured myocyte. The appropriateness of cultured myocytes in the study of the development and physiology of the heart is emphasized by the in vitro formation of T-tubes.Supported by research grants from the Muscular Dystrophy Association, Inc., The Schlieder Foundation, and USPH-Training Grant HL 07098-04. The authors are indebted to Philip Constantin for assistance in dissociating and culturing heart tissue.     

Design and synthesis of sulfonamidophenylethylamides as novel cardiac myosin activator

The sulfonamidophenylethylamide analogues were explored for finding novel and potent cardiac myosin activators. Among them, N-(4-(N,N-dimethylsulfamoyl)phenethyl-N-methyl-5-phenylpentanamide (13, CMA at 10 µM = 48.5%; FS = 26.21%; EF = 15.28%) and its isomer, 4-(4-(N,N-dimethylsulfamoyl)phenyl-N-methyl-N-(3-phenylpropyl)butanamide (27, CMA at 10 µM = 55.0%; FS = 24.69%; EF = 14.08%) proved to be efficient cardiac myosin activators both in in vitro and in vivo studies. Compounds 13 (88.2 + 3.1% at 5 µM) and 27 (46.5 + 2.8% at 5 µM) showed positive inotropic effect in isolated rat ventricular myocytes. The potent compounds 13 and 27 were highly selective for cardiac myosin over skeletal and smooth muscle myosin, and therefore these potent and selective amide derivatives could be considered a new class of cardiac myosin activators for the treatment of systolic heart failure.     

不同剂量舒芬太尼对心脏瓣膜置换术患者应激反应、炎性因子及心肌损伤的影响

目的:探讨不同剂量舒芬太尼对心脏瓣膜置换术患者应激反应、炎性因子及心肌损伤的影响。方法:根据随机数字表法将100例行心脏瓣膜置换术的患者分为低剂量组(n=33,舒芬太尼剂量为1.0μg/kg)、中剂量组(n=33,舒芬太尼剂量为1.5μg/kg)以及高剂量组(n=34,舒芬太尼剂量为2.0μg/kg),比较三组患者应激反应、炎性因子、心肌损伤等指标的变化以及围术期指标情况。结果:中剂量组、高剂量组麻醉诱导后(T1)、插管后1 min(T2)、插管后5 min(T3)、插管后10 min(T4)时间点心率(HR)、平均动脉压(MAP)均低于低剂量组同时间点,且高剂量组低于中剂量组(P<0.05)。与低剂量组比较,中剂量组、高剂量组阻断后30 min(T6)、开主动脉后2h(T7)以及术后1d(T8)时间点白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)均降低(P<0.05)。与低剂量组比较,中剂量组、高剂量组体外循环停机2h(T9)、体外循环停机8h(T10)、体外循环停机24h(T11)、体外循环停机48h(T12)时间点心肌肌钙蛋白I(cTnI)、肌酸磷酸激酶同工酶(CK-MB)均降低(P<0.05)。低剂量组、中剂量组重症监护室(ICU)滞留时间、拔管时间显著短于高剂量组(P<0.05),而三组心血管不良事件发生率比较差异无统计学意义(P>0.05)。结论:给予1.0μg/kg舒芬太尼麻醉的患者应激反应小,1.5μg/kg、2.0μg/kg舒芬太尼可更好地控制心脏瓣膜置换术患者炎性反应,同时对患者心肌损伤有一定的保护作用,但2.0μg/kg舒芬太尼会延长患者ICU滞留时间、拔管时间。     

可视软性喉镜与光棒在颈椎损伤手术患者全身麻醉气管插管中的应用效果比较

目的:比较可视软性喉镜与光棒用于颈椎损伤手术患者全身麻醉气管插管的有效性与安全性。方法:选择2017年1月至2019年2月本院60例高位颈椎骨折需行气管插管全身麻醉的患者,随机分为可视软性喉镜组(U组)和光棒组(G组)各30例。术前所有患者颈托固定,U组使用UE可视软性喉镜行气管插管,G组使用光棒行气管插管,确认气管插管成功后接呼吸机机械通气。比较两组气管插管时间、一次性插管成功率、拔管后口咽部并发症、插管前后的皮层体感诱发电位(CSEP)及运动诱发电位(MMEP)的变化。记录两组患者麻醉前、麻醉诱导后、气管插管后即刻、气管插管后1 min、气管插管后3 min的平均动脉压(MAP)和心率(HR)。结果:U组气管插管时间较G组插管时间长(P0.05);U组和G组气管插管一次性成功率分别为95%和100%;插管后即刻G组患者MAP升高较U明显(P0.05);与U组比较,G组插管后即刻及插管后1 min、3 min的HR升高较明显(P0.05);U组患者口咽部并发症较G组少;两组患者插管后SSEP及MMEP与插管前相比无阳性改变。结论:可视软性喉镜较光棒需要更长的气管插管时间,两者的气管插管一次性成功率均较高,但可视软性喉镜插管期间循环波动较小、术后口咽部并发症较轻,值得临床推广应用。     

注射用地尔硫卓联合前列地尔注射液对射血分数保留型心衰患者心功能、血清炎症因子和氧化应激的影响

摘要 目的：注射用地尔硫卓联合前列地尔注射液对射血分数保留型心衰（HFpEF）患者心功能、血清炎症因子和氧化应激的影响。方法：选取2016年3月至2020年3月期间于齐都医院接受治疗的HFpEF患者108例,根据奇偶排序法分为对照组54例、研究组54例,对照组患者给予注射用地尔硫卓治疗,研究组患者给予注射用地尔硫卓联合前列地尔注射液治疗,疗程为2周。对比两组治疗2周后的疗效,记录两组治疗期间不良反应发生情况。对比两组治疗前、治疗2周后的二尖瓣舒张早期血流峰速度/心房收缩期二尖瓣口最大血流流速（E/A）以及二尖瓣舒张早期血流峰速度/二尖瓣环舒张早期运动峰速度（E/E''）、B型尿钠肽（BNP）、C反应蛋白（CRP）、白细胞介素（IL）-6、巨噬细胞移动抑制因子（MIF）、鸟嘌呤（8-OHdG）、超氧化物歧化酶（SOD）、丙二醛（MDA）。结果：与对照组的总有效率75.93%（41/54）相比,研究组的总有效率92.59%（50/54）更高（P<0.05）。研究组治疗2周后BNP、E/E''低于对照组,E/A高于对照组（P<0.05）。研究组治疗2周后IL-6、CRP、MIF低于对照组（P<0.05）。研究组治疗2周后8-OhdG、MDA低于对照组,SOD高于对照组（P<0.05）。两组均未见明显不良反应发生。结论：注射用地尔硫卓联合前列地尔注射液能显著改善HFpEF患者心功能,改善机体血清炎症因子和氧化应激,安全有效。     

不同浓度罗哌卡因腰硬联合麻醉用于人工髋关节置换手术对患者麻醉效果和术后运动功能的影响

摘要 目的：探讨不同浓度罗哌卡因腰硬联合麻醉用于人工髋关节置换手术对患者麻醉效果和术后运动功能的影响。方法：2017年2月至2019年12月选择在本院进行人工髋关节置换手术的患者84例,根据随机数字表法把患者分为观察组与对照组各42例。两组都给予腰硬联合麻醉,对照组采用常规浓度0.5 %罗哌卡因麻醉观察组采用低浓度0.375 %罗哌卡因麻醉,记录患者麻醉效果和术后运动功能变化情况。结果：观察组的麻醉持续时间、运动恢复时间和感觉运动时间都显著短于对照组(P<0.05)。观察组麻醉后10 min、30 min、60 min的Bromage评分都低于对照组(P<0.05)。观察组术后7 d的低血压、恶心呕吐、头晕头痛、尿潴留等不良反应发生率为7.1 %,显著低于对照组的19.0 %(P<0.05)。两组所有患者在术后2 h、术后4 h、术后24 h的呼吸、心率均在正常范围内波动,组间与组内对比都无统计学意义(P>0.05)。结论：低浓度罗哌卡因腰硬联合麻醉用于人工髋关节置换手术能改善患者的麻醉效果和运动功能,提高麻醉效果,并不影响患者的生命体征,且能减少术后不良反应的发生。